Oncology Impact Fund (Cayman) Management L.P.

CIK 1721036 · last filed 2025-11-25

Oncology Impact Fund (Cayman) Management L.P. is a corporate insider who has filed 10 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing shows the insider sold $1.3M of HOWL on Nov 25, 2025. Across all open-market trades the lifetime net is −$69.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.1M across reported positions. The firm reports its address in Cambridge, MA. 66 SEC filings were submitted jointly with MPM BioImpact LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$5.07M

Companies

3

Total Filings

10

Lifetime Open-Market Net

-$69.30M

Filer Profile

Reported Address

450 KENDALL STREET
CAMBRIDGE, MA 02142

Phone

(617) 425-9200

State of Incorporation

Cayman Islands

Related Filers

MPM BioImpact LLC — 66 joint filings, latest 2025-12-04

UBS Oncology Impact Fund L.P. — 66 joint filings, latest 2025-12-04

ANSBERT GADICKE — 46 joint filings, latest 2025-12-04

MPM Oncology Impact Management GP LLC — 32 joint filings, latest 2021-08-25

MPM ONCOLOGY INNOVATIONS FUND LP — 12 joint filings, latest 2025-12-04

MPM Oncology Innovations Fund GP LLC — 12 joint filings, latest 2025-12-04

MPM ASSET MANAGEMENT LLC — 10 joint filings, latest 2025-12-04

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC — same reported address

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
HOWL	10%+ Owner	5,125,770	$0.99	$5.07M	-$4.36M	3	2025-11-25
iTeos Therapeutics, Inc. (ITOS) Delisted	10%+ Owner	3,452,797	$10.15	$35.05M	-$51.02M	3	2025-05-15
Harpoon Therapeutics, Inc. (HARP) Delisted	10%+ Owner	639,955	$23.01	$14.73M	-$13.92M	4	2021-05-27

Recent Filings

10 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2025-11-25	HOWL	Sell (S)	−1,369,662	-$1.26M	EDGAR
2025-11-20	HOWL	Sell (S)	−1,120,721	-$1.04M	EDGAR
2025-11-06	HOWL	Sell (S)	−1,700,230	-$2.07M	EDGAR
2025-05-15	iTeos Therapeutics, Inc. (ITOS) Delisted	Sell (S)	−4,127,724	-$33.27M	EDGAR
2021-10-12	iTeos Therapeutics, Inc. (ITOS) Delisted	Sell (S)	−348,024	-$9.48M	EDGAR
2021-09-08	iTeos Therapeutics, Inc. (ITOS) Delisted	Mixed	−410,288	-$8.27M	EDGAR
2021-05-27	Harpoon Therapeutics, Inc. (HARP) Delisted	Sell (S)	−85,795	-$1.73M	EDGAR
2021-05-20	Harpoon Therapeutics, Inc. (HARP) Delisted	Sell (S)	−239,740	-$4.91M	EDGAR
2021-04-15	Harpoon Therapeutics, Inc. (HARP) Delisted	Sell (S)	−192,780	-$3.89M	EDGAR
2021-04-13	Harpoon Therapeutics, Inc. (HARP) Delisted	Sell (S)	−154,640	-$3.39M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.